+39 02 610346.1 - info@newron.com

Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website. We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

Latest press releases

  • 14Sep
    Newron reports half-year 2017 results

     

  • 11Jul
    XADAGO® (SAFINAMIDE) NOW AVAILABLE IN THE U.S. FOR PARKINSON’S DISEASE PATIENTS

     

  • 17May
    Newron Pharmaceuticals Announces Expansion of STARS Study to Include Patients Under 13 Years of Age

     

  • 12May
    Newron Receives EUR11.3m Milestone Payments for US Approval of Xadago® (safinamide)

     

  • 11Apr
    Valeo Pharma and Zambon form partnership for Parkinson’s disease treatment Xadago® (safinamide) in Canada

  • 10Apr
    ZAMBON LAUNCHES XADAGO® (safinamide) IN PORTUGAL For patients With mid- to late-stage Parkinson’s Disease

     

View All

Newron share price

Events

  • 27Nov
    German Equity Forum 2017

    Nov, 27-29, 2017 - Frankfurt

  • 15Nov
    Jefferies 2017 London Healthcare Conference

    Nov, 15-16, 2017 - Waldorf Hilton, London

  • 20Sep
    Investora 2017

    Sept. 20-21, 2017 - Zurich, CH

View Event Calendar